Explore 3 Stock Ideas & Industry Insights Download Free Report
The rise contrasted with a weak wider market, as the FTSE 100 dropped more than 1%. Ahead of the results, the shares had been trading around 67.5 pence, close to their 12-month high of 72 pence and well above an early-May low of about …
The trigger was the company's half-year results for the six months to 30 June 2026, published late on 30 September, which gave the market its first full read on how quickly the Tutivia test is scaling now that reimbursement is firmly in place.
Futura Medical plc (LSE:FUM) rose 11.68% on 1 October 2026, putting the stock among the stronger London-listed movers of the session.
ImmuPharma plc (LSE:IMM) rose 7.54% on 1 October 2026, putting the stock among the stronger London-listed movers of the session.
Smith & Nephew PLC (LSE:SN.)shares fell2.64% to 982.40pat the close on Thursday, 1 October 2026, a decline of 26.60p from the previous close of 1,009p. The medical technology group dropped below the 1,000p mark as the FTSE 100 recorded its sharpest daily decline since …
Haleon plc (LSE:HLN)shares fell2.90% to 327.80pat the close on Thursday, 1 October 2026, a decline of 9.80p from the previous close of 337.60p. The consumer healthcare group was among the FTSE 100 fallers as rising bond yields weighed on defensive stocks.The decline leaves Haleon …
Unlike cyclical sectors, Haleon's decline was less about economic exposure and more about valuation mechanics. Companies with steadyEarningsand reliable dividends are often treated as bond proxies, and they tend to struggle when government bond yields rise sharply because fixed income becomes a more attractive …
There was no major company-specific announcement behind the move. Instead, the stock was caught in a wave of selling driven by bond markets, with healthcare names that are typically considered defensive also coming under pressure.
The FTSE 100 dropped 1.68% to 10,428.27 on Thursday, with even defensive sectors such as pharmaceuticals unable to escape theBond Marketsell-off.
The shares had already eased in the previous session, as investors weighed a large new oncology investment against broader market weakness.
We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.
These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.
We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.
These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Download Free Report
Hi! How can we help you today?
Loading…